As part of an international clinical trial, Jacksonville-based Mayo Clinic in Florida has become the first U.S. site to target metastatic breast cancer with the radiopharmaceutical actinium-225. The ...

Mayo Clinic says the therapy uses an alpha-emitting radiopharmaceutical designed to target cancer cells precisely without ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of ...

Overtreatment is considered harmful in terms of decreasing quality of life, wasting resources, and environmental damage.1–3 These risks are especially relevant when considering adjuvant chemotherapy ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

The BEAT Breast Cancer project is funded by the Pfizer Foundation, in collaboration with the Ministry of Health and the ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

By Mariam Sunny (Reuters) -Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's ...